©2024 Stanford Medicine
Study of Aspirin in Patients With Vestibular Schwannoma
Recruiting
I'm InterestedTrial ID: NCT03079999
Purpose
This is a phase II prospective, randomized, double-blind, longitudinal study evaluating
whether the administration of aspirin can delay or slow tumor growth and maintain or improve
hearing in VS patients.
Official Title
Prospective, Randomized, Placebo-Controlled Phase II Trial of Aspirin for Vestibular Schwannomas
Stanford Investigator(s)
Konstantina M. Stankovic, MD, PhD, FACS
Bertarelli Foundation Professor and Professor of Otolaryngology - Head & Neck Surgery (OHNS) and, by courtesy, of Neurosurgery
Eligibility
Inclusion Criteria:
- Radiographic diagnosis of vestibular schwannoma (NF2-associated or sporadic).
- Age≥12 years.
- Ability to provide informed consent.Pediatric patients must provide assent in addition
to their parents'/guardians' consent. Adult patients who cannot consent for themselves
will not be eligible to participate in this study.
- Ability to swallow tablets.
Exclusion Criteria:
- Inability to perform volumetric measurements of vestibular schwannoma(s).
- Inability to tolerate MRI with contrast.
- Daily use of aspirin within the last two months. Occasional use of aspirin for pain
relief is not exclusionary.
- Known allergy to aspirin.
- Impairment of gastrointestinal function or gastrointestinal disease that may
significantly alter the absorption of aspirin.
- Pregnant or lactating women.
- Patients with serious medical illnesses (e.g. severe asthma) that in the option of the
investigator could prevent participation in the trial.
- Active bleeding diathesis.
- Hydrocephalus from brainstem compression.
- Febrile illness or flu-like illness in children and adolescents less than 18 years of
age.
Intervention(s):
drug: Aspirin
drug: Placebo
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Homer Abaya
650-723-7697